Year None202320222021202020192018 Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo® Sep 27, 2023 Read More Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference Sep 21, 2023 Read More Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno Sep 13, 2023 Read More Sensei Biotherapeutics to Participate in Upcoming Investor Conferences Aug 30, 2023 Read More Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Aug 03, 2023 Read More Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference Aug 02, 2023 Read More Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors” Jun 13, 2023 Read More Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors Jun 01, 2023 Read More Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference May 31, 2023 Read More Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights May 09, 2023 Read More Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 24
